GLOBAL PACLITAXEL INJECTION MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024-2031)

Key Developments

• In November 2023, GSK, a biopharmaceutical company, announced that Health Canada, the department of the Government of Canada responsible for national health policy approved a new indication for Jemperli (dostarlimab injection) in combination with carboplatin and paclitaxel for the treatment of adult patients with primary advanced or recurrent mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) endometrial cancer who are candidates for systemic therapy, based on Part 1 of the pivotal RUBY study.
• In May 2023, American Regent, Inc., a pharmaceutical company, announced the launch of Paclitaxel Protein-Bound Particles for Injectable Suspension (Albumin-Bound), an alternative to Abraxane. Paclitaxel Protein-Bound Particles for Injectable Suspension (Albumin-Bound) is a microtubule inhibitor used to treat metastatic breast cancer, non-small cell lung cancer, and pancreatic adenocarcinoma.
• In October 2022, Alembic Pharmaceuticals, a pharmaceutical company, received final approval from the U.S. health agency for its generic version of paclitaxel injection, which is used to treat some types of cancer. The U.S. Food and Drug Administration (FDA) has approved an abbreviated new drug application (ANDA) for Paclitaxel injection in strengths of 30 mg/5 mL (6 mg/mL), 100 mg/16.7 mL (6 mg/mL), and 300 mg/50 mL (6 mg/mL) multiple-dose vials.
• In April 2022, Apotex Inc., a pharmaceutical corporation, announced the release of Paclitaxel protein-bound particles for injection (albumin-bound), a generic form of Abraxane in the U.S. Paclitaxel protein-bound particles for injectable suspension are suggested to treat metastatic breast cancer, non-small cell lung cancer, and pancreatic adenocarcinoma.